Davis Polk advised the underwriters in connection with the SEC-registered offering by The Medicines Company of 5,227,273 shares of common stock for approximately $172.5 million, which includes the full exercise of the underwriters’ option to purchase additional shares from the company.

The Medicines Company is a biopharmaceutical company focused on developing inclisiran, a potentially first-in-class cholesterol-lowering medicine in the subcutaneously administered small interfering RNA class.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associate Young-Min Cho. Partner David R. Bauer and associate Yifu Chen provided intellectual property and technology advice. Partner Michael Farber and associate Daniel L. Jose provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post